U.S., July 23 -- ClinicalTrials.gov registry received information related to the study (NCT07077083) titled 'CAIX PET/CT for Residual or Recurrent Post-ablative ccRCC' on June 24.
Brief Summary: The goal of this clinical trial is to learn whether 89Zr-Girentuximab PET scans can inform management of renal cell carcinoma. The main questions it aims to answer are:
* Does the 89Zr-Girentuximab PET detect ccRCC that is left behind or has come back after treatment?
* What differences can be seen on the 89Zr-Girentuximab PET before and after standard of care treatment?
Participants in arm 1 will be given the study drug followed by a PET scan 3-7 days after injection. Participants in arm 2 will receive the same, but will proceed with their stan...